Apparently that's not news worthy, or the entire company is on vacation. It's difficult to know what they are doing. Maybe this will earn then a small milestone payment. Back to vacation now while the stock price craters.
every time I hear, or say this, it never works out quite as expected. Let's tone it down a little please. We all hope for a big winner, but in this industry risk is high and there are no guarantees of success.
doubtful on all accounts. If IMGN was larger it would be an Icahn value investment. We need an Icahn, not a Buffet. EXAS is up up and away (so far).
I think a lot of those calls will be going out soon, forced liquidation, time to cover, can't spare a share. Shorts must be carping in their pants (pun and misspelling intended).
there's no scooping necessary, I believe the product catches the necessary sample before it hits the water.
$19.05, nearing escape velocity.
I don't see any synergy between Allergan and Salix. Salix looks overbought, a good put buy or put spread candidate to me. IMO of course.
I don't think ACAD will get a bid before approval. If approved, they will be negotiating for rest of world and then maybe someone will suggest, why not just sell it all to us and retire. Just hoping for no FDelays, or negative surprises. FDA seems to want the drug approved, but I don't trust them, or any agency.
the short term action will depend on the reimbursement decision. If the number is good, shorts will be forced to cover at a huge loss and the price could go up sharply. Of course it could be just OK, or not good also. There's a very large short position that is probably getting very nervous.
IMGN shorts are not at all nervous. No news, progress, Bus Dev, nothing for years. One has to wonder WTH these people are doing to earn their high salaries? Several of them, including the CEO need to go. We need an activist and a house cleaning to get the valuation where is should be. Fat chance with this current do-nothing BOD.
I bought stock and sold a few puts, not selling any calls on EXAS. There's no premium in the POS laggard IMGN, so no value in selling calls. We need an activist to get this terrible leadership replaced, they are ruining the company!!!
Checking on coverage. They have to research it and get back with me about the coverage. I also called the company and is sounds like they will be able to ship product very soon, maybe next week.
they have only one way out, acquisition, or a very positive event that creates massive buying volume. Any other exit would cause a price collapse due to the size of their position. They are in until a sale IMO.
My doc gave me a fit kit last year and I never used it. This year I will get the Colo test as soon as it becomes available.
exactly 1) It's a miracle that he said shorts were wrong about anything 2) Sine he's never met a short he didn't love, he set the low-ball number if $1BB in the US, which is about 1/4th to 1/2 of the actual number and then double it, or more for ROW.
yes, this is more accurate, filing around year end after stability tests, approval some time next year, price is anyone's guess. Lately bio-shorts have been shorting into any post-approval rise and betting on a failed, or slow launch. I hope we get a big rise in price and the shorts get crushed, but they seem to win more than they lose and I despise them!!!
yes, I and many here have known this for 25 years. Now just tell us which biotech's have the best products, pipelines, management and relative valuations and we will have something. Which company(s) are the next CELG, REGN, ALXN, etc. IMGN might be rising, but it's rising from the ashes and still a relative laggard/loser.
I don't see much analyst activity, coverage, ratings, etc. I thought the CEO presented well, do they have an active IR leader/program to attract new analyst coverage and investment $$$? If not, they need to beef that up to defend against the criminal shorts.